Lancet neurology

• Latest
• Best
• Search…

• Lancet neurology · Mar 2021

  Comment

  Lessons learned from a progressive supranuclear palsy trial.

  no abstract available

  expand abstract… or not…

• Lancet neurology · Mar 2021

  Comment Letter

  Advanced consent for acute stroke trials.

  no abstract available

  read more… or not…

• Lancet neurology · Mar 2021

  RT-QuIC for detection of prodromal α-synucleinopathies.

  no abstract available

  expand abstract… or just mark as read…

• Lancet neurology · Mar 2021

  The elementary sleep habits of Sherlock Holmes.

  no abstract available

  read on… or not…

• Lancet neurology · Mar 2021

  Randomized Controlled Trial Multicenter Study

  Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

  Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy. ⋯ AbbVie Inc.

  expand abstract… mark as read…